Docs go from bedside manner to biz manager

Pharmas, and their sales reps, need to understand the health economics of a product in differing contexts, according to panelists at the Pharmaceutical Marketing Research Group's (PMRG) third annual meeting.

Concomitant evolutions—in payer structure, the physician's ability to influence the decision about what is prescribed, and managed care decisions—all effect the way brands should be marketed, said Matt Gray, brand insight director, cornerstone business unit, at AstraZeneca. “A front desk person does a lot more than what they used to do” in terms of decision-making, said Gray, a former sales rep.

“For us to keep walking in and saying ‘our product is better than Y,'” is insufficient, said Gray, adding that reps must be able to talk about how a product can be obtained—via formulary or otherwise—and a description of the outcomes. “It's not going to pay for us to say ‘The pill is blue' anymore,” said Gray.

Scott Schaeffer, a practicing family physician on the panel, said that while a focus on comparative effectiveness and the science behind products is important, a lot of decisions are still made “outside of the algorithm.” Ted Lawrence, CEO at Lawrence & Company, added that product economics aren't the last word, since if that were the case, “all hospital formularies would be the same.”

All the panelists agreed that communicating with an entire practice, on top of single physicians, is reflected in the services requested by clients.

You must be a registered member of MMM to post a comment.
close

Next Article in Features

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.